Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Tests PF-07328948 pill in adults with heart failure

Tests a new study pill against a placebo in adults with heart failure.

Key facts

Who runs it
Pfizer
Where
Beijing, Changchun, Changsha, Guangzhou, Haikou, Hengyang, Jinan, Lanzhou, Shanghai, Shijiazhuang, Tianjin, and Xi'an, ChinaSee the 13 sitesAlso in 13 other countries, 139 sites
Registry title
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Status
Recruiting
Phase
Phase 2
People taking part
620 people, planned
Started
19 Jun 2025
Expected to end
5 Jun 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Low Dose PF-07328948
  • Medium Dose PF-07328948
  • High Dose PF-07328948
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to under 80 who have had heart failure for at least 3 months and still have symptoms.

Age
18 years to under 80 years (up to 79 years)
Sex
All sexes can join.
Disease stage
Heart failure diagnosed at least 3 months ago, with New York Heart Association Class II-IV symptoms and left ventricular ejection fraction greater than 40%. Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score below 85 and six-minute walking distance greater than 75 meters.
Earlier treatment
People with known hypersensitivity to an SGLT2 inhibitor, or a contraindication to one, cannot join.

Main reasons for not taking part

  • Type 1 diabetes mellitus or liver cirrhosis
  • Any condition that can affect how the medicine is absorbed into the body
  • Major surgery planned during the study that affects walking ability, in the study doctor's opinion
  • History of heart transplantation, or currently listed for a heart transplant
  • Planned use of IV vasodilators and/or inotropes

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • aged 18 years to < 80 years
  • clinically confirmed to have a diagnosis of heart failure for at least 3 months
  • New York Heart Association Class II-IV symptoms
  • left ventricular ejection fraction greater than 40%
  • Kansas City Cardiomyopathy Questionnaire-23 Total Symptom Score < 85
  • Six-minute walking distance greater than 75 meters

Who cannot take part

  • Major surgery scheduled for the duration of the study, affecting walking ability in the opinion of the study doctor
  • Prior intolerance/known hypersensitivity to an SGLT2 inhibitor or contraindication to an SGLT2 inhibitor
  • Type 1 diabetes mellitus, liver cirrhosis or any condition that can possibly affect how the medicine is absorbed into the body
  • History of heart transplantation, or currently listed for a heart transplant, or current planned use of IV vasodilators and/ or inotropes

Other criteria

  • This study is seeking participants who are:

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in China

Also in 13 other countries, 139 sites

  • Peking University First HospitalBeijing, ChinaTaking people
  • China-Japan Union HospitalChangchun, ChinaTaking people
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
  • Hainan General HospitalHaikou, ChinaTaking people
  • The First Affiliated Hospital of University of South ChinaHengyang, ChinaTaking people
  • Jinan Central HospitalJinan, ChinaTaking people
  • Lanzhou University Second HospitalLanzhou, ChinaTaking people
  • Shanghai Tongji HospitalShanghai, ChinaTaking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
  • The First Hospital of Hebei Medical UniversityShijiazhuang, ChinaTaking people
  • Tianjin People's HospitalTianjin, ChinaTaking people
  • Shaanxi provincial people's hospitalXi'an, ChinaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

The 4 groups in the trial

  • ARM 1Placebo, for comparison

    Placebo Participants will receive Placebo for up to 36 weeks

    Treatment: Placebo

  • ARM 2Treatment being tested

    Low dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Treatment: Low Dose PF-07328948

  • ARM 3Treatment being tested

    Medium dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Treatment: Medium Dose PF-07328948

  • ARM 4Treatment being tested

    High dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks

    Treatment: High Dose PF-07328948

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)
Plain-language title
Tests PF-07328948 pill in adults with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06991257, who can take part
Record updated
23 October 2026